From Creamer Media in Johannesburg, this is the Real Economy Report. The South African Nuclear Energy Corporation, better known as Necsa, is working on two new products to treat cancer. Keith Campbell reports.
Keith Campbell:
The two radiopharmaceuticals are 195m-Platinum-Cisplatin and GluCAB. 195m-Platinum-Cisplatin has been developed in partnership with the Australian Nuclear Science and Technology Organisation. Necsa technology transfer intellectual property analyst Tandokazi Nquma tells us about the 195m-Platinum-Cisplatin project.
Necsa technology transfer intellectual property analyst Tandokazi Nquma
Keith Campbell:
The second product being developed is called GluCAB. Necsa technology transfer office head Theunis Hanekom tells us about it.
Necsa technology transfer office head Theunis Hanekom
Shannon de Ryhove:
Other news making headlines this week: Transnet announces R13-billion in US and Canadian development-finance support for its South African locomotives purchase.
State-owned freight logistics group Transnet has confirmed that it’s received the backing of leading American and Canadian development funding agencies for its purchase of more than 500 diesel and electric locomotives.
Transnet CEO Brian Molefe
That’s Creamer Media’s Real Economy Report. Join us again next week for more news and insight into South Africa’s real economy.